Rituximab biosimilar - Kashiv BioSciences
Latest Information Update: 14 Jan 2022
At a glance
- Originator Therapeutic Proteins International
- Class Anti-inflammatories; Antineoplastics; Antirheumatics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies; Skin disorder therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Autoimmune disorders; Cancer; Transplant rejection
Most Recent Events
- 03 Jan 2019 Kashiv Pharma acquired all the assets of Adello Biologics and changed its name to Kashiv BioSciences
- 16 Nov 2016 Therapeutic Proteins International is now called Adello Biologics
- 24 Jun 2015 Discontinued for Autoimmune disorders in USA (unspecified route)